Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
272lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Learning paths
Pick a track — progress rings update as you complete lessons.
19 lessons
8mResearchAdvanced
Amycretin Beginner's Guide: Novo's GLP-1 + Amylin Dual Agonist
Amycretin puts GLP-1 and amylin in one molecule — with both a pill and a weekly shot in development. Here's the beginner map before Phase 3 ladders finalize.
9mProtocolsIntermediate
Amycretin Dosing Guide: Oral Daily and Weekly Subcutaneous Protocols
Amycretin is Novo's dual GLP-1 + amylin molecule with both oral and injectable programs. Here's the early dosing map and why Phase 3 is the next SEO wave.
8mResearchAdvanced
Amycretin vs CagriSema: One Dual Agonist vs Two-Drug Amylin Stack
Same company family of ideas — GLP-1 + amylin — two product architectures. Here's how amycretin compares to CagriSema without fake head-to-head rankings.
8mProtocolsIntermediate
Cagrilintide Dosing Guide: Solo vs CagriSema 2.4 mg Weekly
Cagrilintide is the amylin half of CagriSema. Here's the dosing map people actually search — 2.4 mg weekly combo context, monotherapy signal, and how not to cross-titrate with eloralintide.
9mPeptidesIntermediate
Eloralintide Beginner's Guide: What LY3841136 Is and Why Amylin Matters
Eloralintide is Lilly's once-weekly selective amylin receptor agonist. If you follow GLP-1s, CagriSema, or retatrutide, this is the next pathway to understand — satiety biology, trial doses, and what the early data actually show.
8mProtocolsIntermediate
Eloralintide Dosing Guide: Phase 2 Doses, Titration, and Weekly Protocol
Searching for eloralintide dosage? Here is the clean map of Phase 2 once-weekly doses, titration arms, and weight-loss results — framed as clinical education, not a DIY protocol.
8mProtocolsIntermediate
Eloralintide + GLP-1 / Tirzepatide: The Amylin Add-On Stack Explained
Amylin + incretin is the stacking thesis behind CagriSema — and now eloralintide. Here's the clinical logic for combining pathways, without turning investigational drugs into DIY stacks.
8mProtocolsIntermediate
How to Reconstitute Eloralintide: Clinical Product vs Research Vials
People searching how to reconstitute eloralintide usually want a retatrutide-style BAC water chart. Here's the honest version — clinical weekly product vs unverified research powder.
7mSafetyIntermediate
Eloralintide Side Effects: What Phase 2 Tolerability Data Suggests
Amylin agonists can feel GLP-1-like in the gut. Here's how to think about eloralintide tolerability, escalation, and symptom tracking without turning trial data into fear content.
7mProtocolsIntermediate
Eloralintide Timing: When to Inject for Best Tolerability
Weekly amylin agonists are not MOTS-c. Here's when to inject eloralintide for tolerability — dose-day meals, evening vs morning, and what to log.
8mResearchAdvanced
Eloralintide vs Cagrilintide: Amylin Agonists Compared
Both hit amylin biology. One is Lilly's Phase 3 monotherapy / combo candidate. The other is the amylin half of CagriSema. Here's a clear comparison for people following the next wave of obesity peptides.
8mResearchAdvanced
Eloralintide vs Petrelintide: Lilly vs Roche Amylin Agonists
Two weekly amylin programs, two sponsors, two data shapes. Here's a clear eloralintide vs petrelintide comparison for people following the next obesity wave.
8mResearchAdvanced
Eloralintide Weight Loss Results: Phase 2 Data and What to Watch in Phase 3
Phase 2 put eloralintide on the board with roughly 9–20% mean weight loss at 48 weeks. Here's the results breakdown — and the troubleshooting mindset for plateaus on any amylin or GLP-1 protocol.
6mResearchBeginner
Macupatide Beginner's Guide: Lilly's LY3532226 Pipeline Peptide
Macupatide is the Lilly code name beside eloralintide that most people skip. This beginner guide explains what it is — and what not to invent about dosing yet.
7mResearchAdvanced
Macupatide and Eloralintide: Lilly's Next Amylin Combination Angle
Eloralintide is only half the Lilly amylin headline. Macupatide shows up in the same ClinicalTrials.gov cluster. Here's the combo literacy guide.
7mResearchAdvanced
Petrelintide Beginner's Guide: Roche/Zealand's Weekly Amylin Analog
Petrelintide is the amylin analog drawing attention for tolerability. This beginner guide covers what it is, what ZUPREME-1 showed, and what to watch next.
8mProtocolsIntermediate
Petrelintide Dosing Guide: Once-Weekly Amylin Analog Titration
Petrelintide is the Roche/Zealand once-weekly amylin analog drawing GLP-1-level attention for tolerability. Here's the Phase 2 dosing pattern, results, and what to track.
8mPeptidesIntermediate
Amylin and GLP-1: The Next Wave of Metabolic Peptides
The next metabolic peptide wave is not just stronger GLP-1 dosing. Amylin, GIP, glucagon, and combination protocols are changing what serious tracking should include.
7mPeptidesIntermediate
CagriSema and Amylin: Why GLP-1 Stacks Are Changing in 2026
GLP-1 therapy is no longer just GLP-1. CagriSema, cagrilintide, petrelintide, and amycretin show why amylin is becoming a serious metabolic target.
Also available at /blog for legacy links.